Sequential Evaluation of NT-proBNP in Heart Failure

Armstrong, Paul W.; Zheng, Yinggan; Troughton, Richard W.; Lund, Lars H.; Zhang, Jian; Lam, Carolyn S.P.; Westerhout, Cynthia M.; Blaustein, Robert O.; Butler, Javed; Hernandez, Adrian F.; Roessig, Lothar; O’Connor, Christopher M; Voors, A.A.

doi:10.1016/j.jchf.2022.04.015

“…В группе верициругата уровень NT-proBNP снижался значительно в большей степени, чем в группе плацебо, и реже повышался в дальнейшем (после 16-й недели). Преимущества верицигуата перед плацебо проявлялись главным образом при значениях этого параметра <8000 пг/мл и еще более отчетливо при уровне <4000 пг/мл [91,92]. Пациенты, у которых значения NT-proBNP находились в четвертом квартиле, отличались рядом неблагоприятных особенностей: у них были ниже исходные скорость клубочковой фильт-НОВЫЕ ПРЕПАРАТЫ КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2023, 32 (1) рации и уровень гемоглобина, чаще встречалась фибрилляция предсердий, реже удавалось достичь целевую дозу верицигуата, таких пациентов чаще включали в исследование в момент госпитализации по поводу декомпенсации СН [83].…”

Section: Socrates-preserved (Ii фаза снсфв) [3]unclassified

Untitled

2023

CPT

0

View full text Add to dashboard Cite

Острое или прогрессирующее ухудшение функции почек при иммуновоспалительных ревматических заболеваниях Нефропатический цистиноз: механизмы развития и лечение АА-амилоидоз почек при артериите Такаясу Гранулематоз с полиангиитом и микроскопический полиангиит: сходства и различия Фармакокинетика препарата Ранквилон ПУЛЬМОНОЛОГИЯ Интерстициальное поражение легких при первичном билиарном холангите Влияние сахарного диабета 2 типа на течение и исходы внебольничной пневмонии Тревога, депрессия и нарушения сна после COVID-19 КАРДИОЛОГИЯ Оценка статуса гидратации у пациентов с острой декомпенсацией хронической сердечной недостаточности Верицигуат в лечении сердечной недостаточности Болезнь Фабри как причина гипертрофической кардиомиопатии Ингибиторы интерлейкина-1 при перикардите

show abstract

“…В группе верициругата уровень NT-proBNP снижался значительно в большей степени, чем в группе плацебо, и реже повышался в дальнейшем (после 16-й недели). Преимущества верицигуата перед плацебо проявлялись главным образом при значениях этого параметра <8000 пг/мл и еще более отчетливо при уровне <4000 пг/мл [91,92]. Пациенты, у которых значения NT-proBNP находились в четвертом квартиле, отличались рядом неблагоприятных особенностей: у них были ниже исходные скорость клубочковой фильт-НОВЫЕ ПРЕПАРАТЫ КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2023, 32 (1) рации и уровень гемоглобина, чаще встречалась фибрилляция предсердий, реже удавалось достичь целевую дозу верицигуата, таких пациентов чаще включали в исследование в момент госпитализации по поводу декомпенсации СН [83].…”

Section: Socrates-preserved (Ii фаза снсфв) [3]unclassified

Vericiguate: a new treatment for chronic heart failure

Khirmanov¹

2023

CPT

0

View full text Add to dashboard Cite

The author reviews the pharmacological properties and clinical trials of vericiguate, a stimulant of soluble guanylate cyclase, that is intended for use in patients with chronic heart failure. The new medicine alleviates unfavorable effects of endothelial dysfunction and other disorders associated with a deficiency of bioavailable nitric oxide and suppressed activity of soluble guanylate cyclase. The efficacy of vericiguate in chronic heart failure with a reduced ejection fraction was established in clinical trials SOCRATES-REDUCED and VICTORIA.

show abstract

“…NT-proBNP is considered the most signi cant biological indicator to assessing HF [24] , It can re ect the severity of heart failure and thus provide effective therapeutic information. After 3 months of treatment, this study found that MHD patients with HFpEF showed a signi cant decrease in plasma NT-proBNP.…”

Section: Discussmentioning

confidence: 99%

Clinical efficacy of sacubitril/valsartan in maintenance hemodialysis patients with HFpEF

Zhao

¹

,

Zhang

²

,

Wu

³

et al. 2023

Preprint

0

View full text Add to dashboard Cite

Background: Heart failure (HF) is a common comorbidity in maintenance hemodialysis (MHD) patients, of which ejection fraction preserved heart failure (HFpEF) is the main cause, resulting in substantial mortality and morbidity. However, there are still no effective therapeutic agents available for HFpEF. Sacubitril/valsartan (SV) has been shown to significantly improve clinical symptoms and reverse ventricular remodeling in patients with reduced ejection fraction of heart failure (HFrEF). The effect of SV in MHD patients with HFpEF remains unclear. Our study aimed to evaluate the efficacy and safety of SV in MHD patients with HFpEF. Methods: A total of 90 MHD patients with HFpEF admitted to the Department of Nephrology of Hefei Second People's Hospital from January 2021 to January 2022 were collected, and they were divided into control group and observation group according to random number method. Both groups received consistent basic treatment based on the results of the test, and at this baseline, one group received ACEI/ARB drugs as the control group, and the other group received SV as the observation group. The starting dose of SV was 50mg bid, and the dose was gradually increased according to blood pressure and blood potassium level until the target dose of 100mg bid was reached for 3 months.After 3 months of treatment, relevant indicators before and after treatment, such as NYHA grade, echocardiography related indicators, NT-proBNP, 6 minute walking distance (6 MWD), blood pressure level, serum potassium and incidence of adverse reactions, were collected and compared. Results: 1. A total of 90 patients with MHD and HFpEF, no patients stopped during the follow-up. There were no significant differences in general clinical data (age, number of months of dialysis, sex, primary disease), NYHA grade, serum NT-proBNP, serum potassium, blood creatinine, hemoglobin, LVEF, 6 MWD, SBP and DBP between the two groups (all P> 0.05).2. After 3 months of treatment, in terms of treatment effect, 41 people were significantly effective, 35 were effective and 14 were ineffective. The efficacy of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P <0.05).3. After 3 months of treatment, LVEF in both groups increased significantly, LVEDD, LVESD, LVEDV, E/e' and PAP decreased compared with the previous group, and the difference before and after treatment in the observation group was more significant than that in the control group, and the difference before and after treatment in both groups was statistically significant (all P<0.05). The LVESV also decreased in both groups, and the difference between the observation group before and after treatment was statistically significant (P<0.05), while the difference between the control group was not statistically significant (P>0.05). 4.After 3 months of treatment, the 6MWD of patients in both groups increased compared with the previous group, and the NT-proBNP decreased compared with the previous group, and the difference before and after treatment in the observation group was higher than that in the control group, and the difference before and after treatment in both groups was statistically significant (both P<0.05). 5. After 3 months of treatment, the average SBP and DBP of the two groups decreased significantly compared with the previous group, and the difference before and after treatment in the observation group was significantly higher than that in the control group, and the difference before and after treatment between the two groups was statistically significant (both P<0.05); There was no significant change in serum potassium levels before and after treatment, and there was no significant difference (all P>0.05). 6. During the treatment follow-up process, the incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P <0.05). Conclusion: Our study shows that SV is effective and safe in the treatment of MHD patients with HFpEF.

show abstract

Sequential Evaluation of NT-proBNP in Heart Failure

Cited by 19 publications

References 9 publications

Untitled

Untitled

Vericiguate: a new treatment for chronic heart failure

Clinical efficacy of sacubitril/valsartan in maintenance hemodialysis patients with HFpEF

Contact Info

Product

Resources

About